Pertuzumab: Effective Targeted Therapy for Breast Cancer Treatment

Summary of Key Points

Pertuzumab is a targeted cancer therapy used to treat specific cancers, including HER2-positive breast cancer. It works by blocking the HER2 protein, which promotes cancer cell growth. Pertuzumab is often combined with other treatments, such as chemotherapy. It is crucial to follow your healthcare provider’s instructions carefully when taking this medication. If you have any questions about your treatment, our telemedicine providers are available to assist you.

Names of Medication

US Brand Name: Perjeta

Generic Name: Pertuzumab

The generic name refers to the active ingredient in the medication, listed in parentheses next to the brand name.

Pharmacologic Category

HER2/neu receptor antagonist

Monoclonal antibody

Dosing Guidelines for Pertuzumab

Pertuzumab is used to treat various cancers, and dosing may vary depending on the specific condition. Always consult your doctor before making any changes to your dose. Below are common dosing guidelines for adults:

Breast Cancer (HER2-positive)

Initial Dose: 840 mg IV (intravenous) over 60 minutes

Maintenance Dose: 420 mg IV every 3 weeks

Duration: Typically administered with other medications like trastuzumab and chemotherapy

Metastatic Breast Cancer

Initial Dose: 840 mg IV over 60 minutes

Maintenance Dose: 420 mg IV every 3 weeks

Duration: Treatment continues until disease progression or unacceptable toxicity

Pertuzumab for Early-Stage Breast Cancer

Initial Dose: 840 mg IV over 60 minutes

Maintenance Dose: 420 mg IV every 3 weeks

Duration: Usually given for 1 year in combination with trastuzumab

Locally Advanced Breast Cancer

Initial Dose: 840 mg IV over 60 minutes

Maintenance Dose: 420 mg IV every 3 weeks

Duration: Typically administered with other cancer treatments

Gastric Cancer and Gastroesophageal Junction Adenocarcinoma

Initial Dose: 840 mg IV over 60 minutes

Maintenance Dose: 420 mg IV every 3 weeks

Duration: Treatment continues until disease progression or unacceptable toxicity

Non-Small Cell Lung Cancer

Initial Dose: 840 mg IV over 60 minutes

Maintenance Dose: 420 mg IV every 3 weeks

Duration: Treatment continues until disease progression or unacceptable toxicity

Ovarian Cancer

Initial Dose: 840 mg IV over 60 minutes

Maintenance Dose: 420 mg IV every 3 weeks

Duration: Typically administered with other cancer treatments

Colorectal Cancer

Initial Dose: 840 mg IV over 60 minutes

Maintenance Dose: 420 mg IV every 3 weeks

Duration: Treatment continues until disease progression or unacceptable toxicity

Dosage Forms and Strengths

Pertuzumab is available in the following intravenous (IV) solutions:

1. 420 mg/14 mL (30 mg/mL)
2. 840 mg/28 mL (30 mg/mL)

Administration Instructions for Pertuzumab

Pertuzumab is administered as an intravenous (IV) infusion, meaning it is delivered through a needle into a vein. The first dose is typically given over 60 minutes, with subsequent doses administered over 30 to 60 minutes. It is important to receive this medication under the supervision of a healthcare provider. If you experience any side effects during the infusion, notify your healthcare provider immediately. You can also reach out to our telemedicine team for support.

Contraindications for Pertuzumab

A contraindication is a specific situation or condition where a treatment or medication should not be used because it may be harmful. For Pertuzumab, certain conditions could lead to serious side effects or complications.

1. Hypersensitivity to Pertuzumab or its components: If you have had an allergic reaction to Pertuzumab or any of its ingredients, it is not safe to take this medication. Allergic reactions can range from mild rashes to severe anaphylaxis, which can be life-threatening.
2. Pregnancy: Pertuzumab can harm an unborn baby. It is contraindicated during pregnancy as it may cause birth defects or pregnancy loss.
3. Severe heart conditions: Patients with a history of heart failure or other severe heart problems may be at increased risk of worsening heart function when taking Pertuzumab. This medication can cause heart-related side effects, especially in those with pre-existing conditions.

Drug-to-Drug Interactions

Some medications can interact with Pertuzumab, potentially increasing the risk of side effects or reducing the effectiveness of either drug. It is important to inform your healthcare provider about all the medications you are taking, including over-the-counter drugs and supplements. Below are some medications that may interact with Pertuzumab:

1. Doxorubicin (Adriamycin): This chemotherapy drug can increase the risk of heart damage when used with Pertuzumab.
2. Trastuzumab (Herceptin): While often used together with Pertuzumab, this combination can increase the risk of heart problems. Your healthcare provider will monitor your heart function closely if these drugs are used together.
3. Paclitaxel (Taxol): This chemotherapy drug is commonly used with Pertuzumab, but it can increase the risk of certain side effects, such as low white blood cell counts.
4. Anthracyclines (e.g., Epirubicin): These drugs are known to cause heart damage, and using them with Pertuzumab may increase the risk of heart-related side effects.

Pertuzumab in Pregnancy

Is it Safe to Take Pertuzumab During Pregnancy?

No, it is not safe to take Pertuzumab during pregnancy. As a targeted cancer therapy, Pertuzumab can pose serious risks to an unborn baby, potentially leading to birth defects or pregnancy loss. If you are pregnant or planning to become pregnant, it is crucial to discuss alternative treatment options with your healthcare provider. Should you become pregnant while taking Pertuzumab, contact your healthcare provider immediately. They may recommend discontinuing the medication and exploring other treatment approaches.

Pertuzumab While Breastfeeding

Is it Safe to Take Pertuzumab While Breastfeeding?

Breastfeeding while taking Pertuzumab is not advised. Although there is limited data on whether Pertuzumab passes into breast milk, the potential risk to a nursing infant suggests avoiding breastfeeding during treatment. If you are currently breastfeeding or planning to breastfeed, consult your healthcare provider to carefully weigh the risks and benefits of continuing Pertuzumab. They can help you make an informed decision about your treatment and your baby’s health.

Estimated Cost of Pertuzumab Treatment

The cost of Pertuzumab treatment can vary depending on your location and the pharmacy you use. Without insurance, a 30-day supply of Pertuzumab with a GoodRX coupon is estimated to cost between $5,000 and $6,000. Prices may fluctuate, so it’s a good idea to check with your pharmacy or use a prescription discount service to find the most affordable option.

Possible Alternatives to Pertuzumab

If Pertuzumab is not suitable for you, or if you are considering alternative treatments, several options are available depending on your specific condition. Always consult your healthcare provider before making any changes to your treatment plan. Our telemedicine providers are also available to discuss these alternatives with you.

Breast cancer treatment: Alternatives may include other targeted therapies like Trastuzumab (Herceptin) or chemotherapy options such as Paclitaxel (Taxol). Hormonal therapies like Tamoxifen may also be considered for certain types of breast cancer.

HER2-positive breast cancer: Other targeted therapies include Trastuzumab (Herceptin) and Lapatinib (Tykerb). Chemotherapy or radiation therapy may also be part of the treatment plan.

Metastatic breast cancer: Treatment options may involve hormonal therapies, chemotherapy, or other targeted therapies like Ado-trastuzumab emtansine (Kadcyla).

Early-stage breast cancer: Common treatments include surgery, radiation, and chemotherapy. Hormonal therapies may be used for hormone receptor-positive cancers.

Locally advanced breast cancer: Treatment may involve a combination of surgery, radiation, chemotherapy, and targeted therapies like Trastuzumab (Herceptin).

Gastric cancer: Chemotherapy, radiation, and surgery are common treatments. Targeted therapies like Trastuzumab (Herceptin) may also be used for HER2-positive gastric cancer.

Gastroesophageal junction adenocarcinoma: Treatment options may include chemotherapy, radiation, and surgery. Targeted therapies like Trastuzumab (Herceptin) may also be considered.

Non-small cell lung cancer: Depending on the stage, treatment may include surgery, radiation, chemotherapy, or targeted therapies like Osimertinib (Tagrisso).

Ovarian cancer: Treatment options include surgery, chemotherapy, and targeted therapies like Bevacizumab (Avastin).

Colorectal cancer: Treatment may involve surgery, chemotherapy, radiation, and targeted therapies like Cetuximab (Erbitux).

Recent Updates on Pertuzumab Research

Recent studies continue to explore the effectiveness of Pertuzumab in combination with other therapies for HER2-positive cancers. One area of ongoing research is the use of Pertuzumab and chemotherapy alongside Trastuzumab for early-stage HER2-positive breast cancer. Clinical trials have shown that this combination significantly improves survival rates and reduces the risk of cancer recurrence. Researchers are also investigating the potential use of Pertuzumab in other HER2-positive cancers, such as gastric and ovarian cancer.

As research progresses, new findings may expand the use of Pertuzumab to other cancer types or refine its role in combination therapies. If you are interested in learning more about ongoing clinical trials or new treatment options, speak with one of our telemedicine providers. They can guide you through the latest research and help determine the best treatment plan for your condition.

James Kingsley

Learn More